A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
Melanoma · Lymphoma · Solid Tumor · Classical Hodgkin Lymphoma · Microsatellite-instability-high Solid Tumor
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.9
5 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Score over time
- Stage
- Phase 1/2
- Patients
- 370 (planned)
- Started
- Mar 19, 2015
- Main results expected
- Feb 2, 2028
- Fully finished
- Feb 2, 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Objective Response Rate (ORR) by Response Evaluation Criteria in Solid Tumors and Other Lymphoma Version 1.1 (RECIST 1.1) per Site Assessment (Each Disease Indication Evaluated Separately)
Measured over: Up to 2 years
ORR by RECIST 1.1 per Site Assessment for MSI-H or TMBH Solid Tumors (Each Cohort Evaluated Separately)
Measured over: Up to 2 years
ORR by International Working Group (IWG) Response Criteria (Cheson, 2007) per Blinded Independent Central Review (BICR) Assessment for rrcHL Cohort
Measured over: Up to approximately 2 years
Number of Participants with Dose-Limiting Toxicities (DLTs)
Measured over: Cycle 1 (Up to 21 days)
Number of Participants Experiencing Adverse Events (AEs)
Measured over: Up to 27 months
Number of Participants Discontinuing Study Drug Due to AEs
Measured over: Up to 2 years
Changes Tremor has spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- none yet
Trial ID NCT02332668 · record last updated 2026-07-06 · checked 2026-11-09 15:47 UTC